All In Biotech

Drug Trial Radar · NCT05266560

Effects of Ciprofol Anesthesia on Learning and Memory Function and Antidepressant Effects of ECT in Depressive Patients

Effects of Ciprofol Anesthesia on Learning and Memory Function and Antidepressant Efficacy of ECT in Patients With Depression

Last checked: Nov 20, 2026Latest source record: Mar 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

390

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Jul 1, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
First Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical study, propofol was used as the positive control, and a randomized controlled trial design was used to observe the effects of ciprofol anesthesia on learning and memory function and antidepressant efficacy in patients with ECT. A total of 390 depressed patients who were to undergo electroconvulsive therapy were selected and randomly divided into two groups, namely the propofol group (n=195 cases) and the ciprofol group (n=195 cases). The patients in the propofol group were given propofol 1.5mg/kg + succinylcholine 1mg/kg, and the patients in the ciprofol group were given ciprofol 0.4mg/kg and succinylcholine 1mg/kg, and the patients were given electroshock after anesthesia treat.

Conditions

  • Depressive Disorder

Interventions

  • ciprofolDrug

    A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.

  • PropofolDrug

    Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cognitive impairment rate within 24 hours after the whole ECT courseTime frame: After the patient received MECT treatment within 24 hours after the whole ECT course

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.